Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e006464
DOI: 10.1136/jitc-2022-006464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 23.02.2023. Verfasst von WeiQing Venus So und 3 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Roche Innovation Center New York, Little Falls, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
Many biomarkers have been proposed to be predictive of response to anti-programmed cell death protein-1 (PD-1)/anti-programmed death ligand-1 (PD-L1) checkpoint inhibitors (CPI). However, conflicting observations and lack of consensus call for an assessment of their clinical utility in a large data set. Using a combined data set of clinical trials and real-world data, we assessed the predictive and prognostic utility of biomarkers for clinical outcome of CPI in non-small cell lung cancer (NSCLC).
Methods
Retrospective cohort study using 24,152 patients selected from 71,850 patients with advanced NSCLC from electronic health records and 9 Roche atezolizumab trials. Patients were stratified into high and low biomarker groups. Correlation with treatment outcome in the different biomarker groups was investigated and compared between patients treated with CPI versus chemotherapy. Durable response was defined as having complete response/partial response without progression during the study period of 270 days.
Results
Standard blood analytes (eg, albumin and lymphocyte) were just prognostic, having correlation with clinical outcome irrespective of treatment type. High expression of PD-L1 on tumors (≥50% tumor cell staining) were specifically associated with response to CPI (OR 0.20; 95% CI 0.13 to 0.30; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Data Science, Roche Innovation Center New York, Little Falls, New Jersey, USA.
- Department of Biostatistics, F Hoffmann-La Roche Ltd, Basel, Switzerland.
- Roche Innovation Center Basel, F Hoffmann-La Roche Ltd, Basel, Switzerland.
- Roche Innovation Center Zurich, F Hoffmann-La Roche Ltd, Schlieren, Switzerland jehad.charo@roche.com.
ORCID-Profile: WeiQing Venus So, Jehad Charo
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
So, W. V., Dejardin, D., Rossmann, E., & Charo, J. (2023). Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. Journal for ImmunoTherapy of Cancer, 11(2), e006464. https://doi.org/10.1136/jitc-2022-006464
Vancouver
So WV, Dejardin D, Rossmann E, Charo J. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. Journal for ImmunoTherapy of Cancer. 2023;11(2):e006464. doi:10.1136/jitc-2022-006464
BibTeX
@article{So2023,
author = {So, WeiQing Venus and Dejardin, David and Rossmann, Eva and Charo, Jehad},
title = {Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {2},
pages = {e006464},
doi = {10.1136/jitc-2022-006464}
}
EUVIMED